Leucovorin (Folinic Acid)

Folinic acid provides a reduced form of folate that bypasses the dihydrofolate reductase step, directly entering the tetrahydrofolate pool. This supports nucleotide synthesis and methylation reactions, allowing cells to continue DNA replication and repair even when antifolate drugs block the normal folate pathway.

The dose of Leucovorin is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and concurrent therapies. Healthcare professionals determine the appropriate amount and schedule for each patient.

Leucovorin should only be used during pregnancy or lactation when clearly indicated and after a risk‑benefit assessment by a qualified obstetrician or maternal‑fetal specialist. Potential benefits must outweigh any unknown risks to the fetus or infant.

To order Leucovorin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Unlike folic acid, which requires metabolic activation, folinic acid is already in a reduced form and can be utilized directly by cells. This makes Leucovorin effective for rescuing cells during antifolate chemotherapy and for patients with impaired folate metabolism, whereas regular folic acid may not provide the same rapid therapeutic benefit.

Leucovorin should be stored below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintain a stable environment and avoid freezing. Follow any additional handling instructions provided by the supplier to preserve sterility and potency.

Leucovorin is supplied as a sterile solution for injection and can be given via epidural, intrabursal or intracoronary routes, depending on the clinical indication. Administration is performed by qualified healthcare professionals following aseptic technique and the prescribing information.

Serious risks include severe allergic reactions (anaphylaxis), acute renal impairment, significant electrolyte disturbances, and unexplained bleeding or bruising. Patients should be monitored closely for these events, and any signs of severe reaction require immediate medical attention.

Leucovorin is contraindicated in patients with known hypersensitivity to folinic acid or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnancy unless the potential benefit justifies the risk.